Please assess the completion status of the following clinical trial:

Trial Title: Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Within 24 hours of admission;~2. Aged between of 40 and 80 years old;~3. Established clinical history of COPD with spirometry-verified COPD (defined as post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ≤ 0.70);~4. AECOPD diagnosis in accordance with the GOLD guideline (An acute worsening of respiratory symptoms that result in additional therapy)12;~5. Current or former cigarette smokers (≥10 packs per year);~6. Blood eosinophil count \> 2% or \>300 cells/μL tested within 24 hours of admission;~7. Signed informed consent.~Exclusion Criteria:~1. Admission due to other diseases (pneumonia, pneumothorax, pulmonary interstitial disease, active tuberculosis or bronchiectasis, ect);~2. Regular use of glucocorticoid ≥3 months;~3. Received prednisone ≥ 60 mg in the past three days (or equivalent doses of other corticosteroid);~4. Allergic or intolerant to corticosteroid;~5. Participating in or completed another drug trial within 90 days;~6. Pregnancy or lactation;~7. Severe COPD exacerbation requiring invasive mechanical ventilation (IMV) or transfer to ICU within 24 hours after emergency admission or hospitalization;~8. With complications that may cause eosinophilia;~9. Pulmonary embolism within the past two years;~10. Myocardial infarction, uncontrollable congestive heart failure or arrhythmia within the past four weeks;~11. Comorbidity that may influence the immune system;~12. Malignant tumor;~13. Neuromuscular disease affecting the respiratory system;~14. Systemic fungal infection;~15. Thoracotomy or bronchoscopic lung volume reduction surgery history;~16. Adrenocortical insufficiency history;~17. Diabetes mellitus with poor glycemic control;~18. Uncontrollable severe psychiatric illnesses even with medication, cognitive impairment, and severe language difficulties;~19. ALT ≥ 100U/L or AST ≥ 80U/L;~20. Serum creatinine ≥ 162umol/L;~21. Life expectancy of less than 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Systemic corticosteroid group (Type: EXPERIMENTAL): Patients will receive Oral prednisone 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization.
- Control group (Type: PLACEBO_COMPARATOR): Participating patients will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).